Comparison of simian virus 40 large T antigen recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis.
Comparison of simian virus 40 large T antigen recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis.
复制标题
猿病毒40大T抗原重组蛋白和DNA免疫诱导实验性肺转移保护性免疫的比较。
DOI：
10.1007/s002620050540
复制
发表时间：
1999
期刊：
影响因子：
--
通讯作者：
Kennedy,RC
中科院分区：
文献类型：
--
作者：
Watts,AM;Shearer,MH;Pass,HI;Bright,RK;Kennedy,RC
在这份报告中，我们研究了重组肿瘤抗原制剂的能力，以防止建立实验性肺转移。将杆状病毒衍生的重组猴病毒40（SV 40）大肿瘤抗原（T-Ag）注射到BALB/c小鼠体内，然后静脉注射同基因SV 40转化的致瘤细胞进行攻击。实验鼠肺转移模型允许使用计算机辅助视频图像分析在攻击后的不同时间准确测量肺中的转移性病变。攻击后，获得小鼠组的肺转移和存活数据。用重组SV 40 T-Ag免疫的动物在攻击后没有检测到肺转移的迹象，并且存活超过120天。用酶联免疫吸附试验检测免疫小鼠血清中抗SV 40 T-Ag的抗体。从用重组SV 40 T-Ag免疫的小鼠获得的脾细胞不裂解同源肿瘤细胞，表明未诱导细胞毒性T淋巴细胞应答。对照小鼠在攻击后4周内发生广泛的肺转移并死于致命肿瘤。这些数据表明，在实验性肺肿瘤转移模型中，用重组SV 40 T-Ag免疫诱导保护性T-Ag特异性免疫。
In this report we examine the ability of a recombinant tumor antigen preparation to prevent the establishment of experimental pulmonary metastasis. Baculovirus-derived recombinant simian virus 40 (SV40) large tumor antigen (T-Ag) was injected into BALB/c mice followed by challenge with an intravenous injection of syngeneic SV40-transformed tumorigenic cells. The experimental murine pulmonary metastasis model allows for the accurate measurement of metastatic lessions in the lungs at various times after the challenge, using computer-assisted video image analysis. Following challenge, lung metastasis and survival data for the groups of mice were obtained. Animals immunized with recombinant SV40 T-Ag showed no detectable sign of lung metastasis and survived for more than 120 days after challenge. Antibodies specific for SV40 T-Ag were detected in the serum of immunized mice by enzyme-linked immunosorbent assay. Splenocytes obtained from mice immunized with recombinant SV40 T-Ag did not lyse syngeneic tumor cells, indicating that no cytotoxic T lymphocyte response was induced. Control mice developed extensive lung metastasis and succumbed to lethal tumor within 4 weeks after challenge. These data indicate that immunization with the recombinant SV40␣T-Ag induces protective, T-Ag-specific immunity in an experimental pulmonary tumor metastasis model.